DOT1L and acute myeloid leukemia: Hence, inhibition of Dot1L, the only known H3K79 methyltransferase in humans, is a promising therapeutic strategy against AML, although recently concluded phase I studies have shown modest effects of a highly specific Dot1L inhibitor, Pinometostat (EPZ-5676) (60).